Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis

Blood

Volumn 120, Issue 3, 2012, Pages 569-571

  Barbui, Tiziano ^a   Thiele, Jürgen ^b   Carobbio, Alessandra ^a   Passamonti, Francesco ^c   Rumi, Elisa ^d   Randi, Maria Luigia ^e   Bertozzi, Irene ^e   Vannucchi, Alessandro M ^f   Gisslinger, Heinz ^g   Gisslinger, Bettina ^g   Finazzi, Guido ^a   Ruggeri, Marco ^h   Rodeghiero, Francesco ^h   Rambaldi, Alessandro ^a   Gangat, Naseema ⁱ   Tefferi, Ayalew ⁱ  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c OSPEDALE DI CIRCOLO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h SAN BORTOLO HOSPITAL   (Italy)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; LACTATE DEHYDROGENASE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE COURSE; EVENT FREE SURVIVAL; FOLLOW UP; GENE; GENE MUTATION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; JAK2 GENE; MAJOR CLINICAL STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREFIBROTIC PRIMARY MYELOFIBROSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS;

EID: 84864136100     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-407981     Document Type: Article

References (22)

1. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353(1):33-45. (Pubitemid 41007805)
2. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165(22):2651-2658. (Pubitemid 41785064)
3. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.
4. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-166. (Pubitemid 43205767)
5. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-276. (Pubitemid 46158119)
6. Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biological features, treatment, and long-term outcome. Blood. 2012;119(10):2219-2227.
7. Finazzi G, Ruggeri M, Rodeghiero F, et al. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood. 2003; 101(9):3749. (Pubitemid 36857968)
8. Alvarez-Larrán A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-1223. (Pubitemid 46831811)
9. Palandri F, Polverelli N, Ottaviani E, et al. Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica. 2010;95(6): 1038-1040.
10. Barbui T. How to manage children and young adults with myeloproliferative neoplasms [published online ahead of print January 18, 2012]. Leukemia. doi:10.1038/leu.2012.12.
11. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
12. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22(1):14-22.
13. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85(1):62-69.
14. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1104 patients. J Clin Oncol. 2011;29(23):3179-3184.
15. Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34(1):29-39. (Pubitemid 27063140)
16. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Vol 3. Lyon, France: International Agency for Research on Cancer; 2001.
17. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
18. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132. (Pubitemid 41323513)
19. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22):5857-5859.
20. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716-719.
21. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3): 840-846. (Pubitemid 47267419)
22. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis. A systematic review. Thromb Res. 2009;124(4):409-417.